Gal-9 serum and mRNA levels were also elevated in post- versus pre-treatment NSCLC patient cohorts undergoing EGFR tyrosine kinase inhibitor (TKI) therapy, illuminating Gal-9 as a potential mediator of acquired resistance to EGFR-TKI treatment [236]. Here, EGFR is linked to non-small cell lung carcinoma.